Literature DB >> 23912480

Associations between bullous pemphigoid and primary malignant cancers: an English national record linkage study, 1999-2011.

Eugene Ong1, Raph Goldacre, Uy Hoang, Rodney Sinclair, Michael Goldacre.   

Abstract

We conducted a nationwide record-linked study using all English NHS hospital admission data and mortality statistics from 1999 to 2011 to evaluate the risk of concurrent or subsequent bullous pemphigoid (BP) in a cohort of 2,873,720 individuals with malignant cancers, when compared with a reference cohort. We calculated standardised rate ratios (RRs) based on person-years at risk, comparing the observed and expected numbers of BP cases in the cancer cohort with those in the reference cohort. Overall, the cohort of people with a record of a malignant cancer was not found to be at greater risk of concurrent or subsequent BP than the cohort of people without a record of a malignant cancer (RR 0.96, 95 % CI 0.88-1.04), although elevated risks of BP were found in sub-cohorts of people with either kidney cancer, laryngeal cancer or lymphoid leukaemia. We also similarly analysed the risk of concurrent and subsequent malignant cancers in a cohort of people with a principal diagnosis of BP, and again found no increased risk as compared with the reference cohort (RR 1.00, 95 % CI 0.92-1.09).

Entities:  

Mesh:

Year:  2013        PMID: 23912480     DOI: 10.1007/s00403-013-1399-5

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  12 in total

1.  Malignancies in pemphigus and pemphigoid diseases.

Authors:  Franziska Schulze; Kathrin Neumann; Andreas Recke; Detlef Zillikens; Roland Linder; Enno Schmidt
Journal:  J Invest Dermatol       Date:  2015-01-05       Impact factor: 8.551

Review 2.  Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management.

Authors:  Kyle T Amber; Dedee F Murrell; Enno Schmidt; Pascal Joly; Luca Borradori
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

Review 3.  [Bullous pemphigoid: diagnosis and therapy].

Authors:  Andrea Kneisel; Michael Hertl
Journal:  Wien Med Wochenschr       Date:  2014-07-31

Review 4.  [Paraneoplastic autoimmune dermatoses].

Authors:  D Didona; M Hertl
Journal:  Hautarzt       Date:  2021-03-01       Impact factor: 0.751

5.  Treatment of Bullous Pemphigoid in People Aged 80 Years and Older: A Systematic Review of the Literature.

Authors:  Meital Oren-Shabtai; Noa Kremer; Moshe Lapidoth; Eran Sharon; Lihi Atzmony; Adi Nosrati; Emmilia Hodak; Daniel Mimouni; Assi Levi
Journal:  Drugs Aging       Date:  2020-11-24       Impact factor: 3.923

6.  Biliary Tract and Liver Complications in Polycystic Kidney Disease.

Authors:  Parminder K Judge; Charlie H S Harper; Benjamin C Storey; Richard Haynes; Martin J Wilcock; Natalie Staplin; Raph Goldacre; Colin Baigent; Jane Collier; Michael Goldacre; Martin J Landray; Christopher G Winearls; William G Herrington
Journal:  J Am Soc Nephrol       Date:  2017-05-02       Impact factor: 10.121

Review 7.  Bullous Pemphigoid Associated with Anti-programmed Cell Death Protein 1 and Anti-programmed Cell Death Ligand 1 Therapy: A Review of the Literature.

Authors:  Aikaterini Tsiogka; Johann W Bauer; Aikaterini Patsatsi
Journal:  Acta Derm Venereol       Date:  2021-01-20       Impact factor: 3.875

Review 8.  Bullous pemphigoid.

Authors:  Denise Miyamoto; Claudia Giuli Santi; Valéria Aoki; Celina Wakisaka Maruta
Journal:  An Bras Dermatol       Date:  2019-05-09       Impact factor: 1.896

9.  Increased Risk of Squamous Cell Carcinoma of the Skin and Lymphoma Among 5,739 Patients with Bullous Pemphigoid: A Swedish Nationwide Cohort Study.

Authors:  Zeyad Albadri; Kristofer Thorslund; Henrike Häbel; Oliver Seifert; Carina Grönhagen
Journal:  Acta Derm Venereol       Date:  2020-10-14       Impact factor: 3.875

10.  Nontargeted Effect after Radiotherapy in a Patient with Non-Small Cell Lung Cancer and Bullous Pemphigoid.

Authors:  Carsten Nieder; Khalid Al-Shibli; Terje Tollåli
Journal:  Case Rep Oncol Med       Date:  2015-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.